Abstract 1602 Table 1
Baseline Characteristics of NEA Clusters 1,2 and 3
CharacteristicCluster 1
n = 9
IFN LO
Cluster 2
n = 36
GLOBAL HI
Cluster 3
n = 40
N/M LOW PL HI
p value
Female, (%) 8 (88.9) 33 (91.7) 34 (85.0) 0.66
Ancestry, n (%)
Subcontinental Asian
Chinese and Other Asian
African including mixed race
Other including mixed race not otherwise specified
3 (33.3)
0 (0.0)
4 (44.4)
2 (22.2)
11 (30.6)
7 (19.4)
13 (36.1)
5 (13.9)
13 (32.5)
4 (10.0)
17 (42.5)
17 (42.5)
0.78
Age (years), mean (95% CI ) 45 (35, 54) 35 (31, 41) 37 (32,41)
Disease duration (years), mean (95% CI ) 17 (6, 16) 14 (11,17) 12 (8,15)
BILAG A or B score, n (%)
Mucocutaneous
Musculoskeletal
Renal
1 (11.1)
2 (22.2)
4 (44.4)
12 (33.3)
16 (44.5)
15 (41.7)
18 (45.0)
15 (45.5)
18 (48.6)
0.39
0.70
0.9
BILAG numerical score, mean (95% CI ) 16.5 (12.6, 20.3) 19.5 (16.2, 22.8) 19.4 (15.9, 22.9)
SLEDA-2K, mean (95% CI ) 5.8 (1.0, 10.7) 10.6 (8.6, 12.6) 9.9 (7.4,12.3)
SLICC damage index, mean (95% CI ) 1.13 (0, 2.3) 0.8 (0.2, 1.4) 1.03 (0.5, 1.5)
Full blood count, mean (95% CI )
Hb
Neutrophils
Lymphocytes
116.1 (98.0, 134.3)
9.6 (5.0,14.2)
1.83 (1.0, 2.6)
110.23 (103.1, 117.3)
6.0 (4.7, 7.2)
0.79 (0.61, 1.0)
120.3 (112.4, 128.4)
4.0 (2.7, 5.5)
1.61 (1.1, 2.1)
Total IgG (g/L), mean (95% CI ) 7.5 (6.1, 8.9) 17.2 (14.8, 20.0)* 16.9 (14.2, 19.6)** * 0.038
** 0.084
Low C3 or C4, n (%) *no missing data 3 (33.3) 21 (61.8) 24 (50.0) 0.29
Concurrent Immunosuppressant, n (%)
Any agent (MMF, CsA, Tac, MMF, AZA)
Mycophenolate mofetil
Azathioprine
2 (22.2)
1 (11.1)
0 (0.0)
15 (38.5)
13 (36.1)
3 (8.3)
22 (55.0)
18 (45.0)
2 (5.0)
0.16
0.16
0.60
Anti-malarial, m (%) 5 (55.6) 18 (50.0) 21 (47.7) 0.95
Oral prednisolone dose (mg), mean (95% CI ) 19.9 (13.0, 26.6) 11.7 (8.3, 15)* 11.3 (8.9,13.7)** * 0.033
**0.021
RTX response analysis n = 45
BILAG response (6 months), n/N (%)
1/7 (14.3) 16/19 (84.2) 8/19 (42.1) 0.002